Please login to the form below

Not currently logged in
Email:
Password:

DynaVax

This page shows the latest DynaVax news and features for those working in and with pharma, biotech and healthcare.

Dynavax receives FDA green light for hepatitis B vaccine

Dynavax receives FDA green light for hepatitis B vaccine

Dynavax receives FDA green light for hepatitis B vaccine. Heplisav-B becomes first and only two-dose hep B vaccine approved in the US. ... Dynavax expects to launch its vaccine in the US in the first quarter of 2018.

Latest news

  • FDA gives priority review for Keytruda in lung cancer FDA gives priority review for Keytruda in lung cancer

    A just-signed agreement with Dynavax will see Keytruda and another Merck compound - anti-interleukin-10 drug MK-1966 - tested alongside Dynavax' SD-101, a toll-like receptor 9 (TLR9) agonist

  • Kane & Finkel closes Kane & Finkel closes

    The agency was hit first when the FDA denied approval of Dynavax Technologies' adult hepatitis B vaccine Heplisav.

  • FDA approves Sanofi's four-in-one flu vaccine FDA approves Sanofi's four-in-one flu vaccine

    FDA approves Sanofi's four-in-one flu vaccine. But wants more safety data for hepatitis B vaccine from Dynavax. ... Eddie Gray, CEO of Dynavax, said the company appreciated “ the informative interactions and clarity” provided by the FDA.

  • Dynavax and Merck & Co team up for phase III Hep B vaccine

    Dynavax will continue to manage ongoing phase III studies in Canada and the EU, as well as other licensure-required studies. ... Production of the vaccine will be expanded at a new facility to support expected market needs, according to Dynavax.

  • Attacking asthma

    Another approach using a vaccine (ISS; Dynavax) is being trialled in patients with persistent disease.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Pfizer veteran joins Dynavax board Pfizer veteran joins Dynavax board

    Pfizer veteran joins Dynavax board. Natale Ricciardi spent 39 years at pharma giant. ... Natale Ricciardi has joined the board of Dynavax Technologies two years after retiring from Pfizer.

  • David Novack leaves Novartis for Dynavax David Novack leaves Novartis for Dynavax

    David Novack leaves Novartis for Dynavax. Was global head of technical operations and supply chain for diagnostics at Swiss pharma firm. ... Vaccines-focused biopharma Dynavax has appointed David Novack, formerly of Novartis, to be its senior VP of

  • Andrew Gengos joins ImmunoCellular as CEO Andrew Gengos joins ImmunoCellular as CEO

    He has also spent time at Dynavax Technologies, Chiron Corporation and McKinsey &Company.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics